Morningside

We support start-ups with investments between $10M and $20M in Europe, Israel and opportunistically on the East coast of the US. Forestay is more than just a VC fund, it’s a family. Forestay was founded as the digital tech arm of a family-oriented investment group that traces its successes in business and its enduring values back across generations. The Bertarelli family founded B-FLEXION (formerly Waypoint Capital), of which Forestay is a part, in 2012 to evolve the management of the capital realised by the sale of Serono, the global leader in biotech and healthcare that they had grown over three generations of leadership. In the decade since, B-FLEXION and its businesses have generated exceptional and lasting value. B-FLEXION is an entrepreneurial private investment firm that partners with sophisticated capital to deliver exceptional value over the generations. As well as its investment funds seeding and building businesses in technology, private equity, real estate and hedge funds, B-FLEXION also focuses on growing operating businesses in transformative industries. Building on its heritage and of that of its founder and Chairman, these have been principally in life sciences, healthcare and digital health.

We are in the age of discovery, seizing a unique moment in time. Every generation experiences a breakthrough that alters the world. Technology has transformed virtually every aspect of our lives, and now it’s healthcare’s turn. aMoon is here to accelerate this transformation. We partner with exceptional entrepreneurs who harness groundbreaking science and technology to transform healthcare. Through aMoon Velocity and aMoon Growth, we invest in early and late-stage companies pursuing disruptive, cutting-edge solutions for high unmet medical needs. We build bridges between our portfolio companies and global tech, finance and medical research hubs to enable entrepreneurs to turn their vision into reality.

We invest in the innovators behind the miracles of science who are passionate about improving human health. Sanofi Ventures serves as an entry point to the innovation ecosystem for Sanofi, strategically investing in early-stage transformational science and technology, when companies are too early to partner with or acquire. Our Approach As the corporate venture capital arm of Sanofi, we invest in top-tier biotech and digital health companies that focus on helping patients and transforming the practice of medicine. We invest across all stages of the private company lifecycle, from Seed to Series B and beyond, while leading financings, serving on boards, and taking pride in working alongside portfolio companies to drive long-term value through future financings and IPO. How We Work Think of us like institutional venture capitalists with an added bonus: in addition to our investment, we aim to offer our portfolio companies select access to Sanofi’s expertise and capabilities in science, preclinical and clinical development, regulatory, data analytics, manufacturing, market access, and commercialization. Our goal is to foster strong relationships over time so when our portfolio company is ready to consider a partnership or acquisition, our colleagues on the BD and M&A teams can be a first and last call. We move quickly, we don’t believe in drawn-out processes, and we always aim to provide thoughtful feedback. Our Investment Focus We invest in early-stage biotech and digital health companies of strategic interest to Sanofi. We seek to accelerate all strategic focus while reaching into novel and emerging areas of science and technology. Here are some of the areas that we currently are thinking about: Rare diseases Immunology and inflammation Oncology Cell and gene therapy Vaccines Digital health and data science We can't do it alone - we would love to hear how we can team up to improve human health for people everywhere!

Our portfolio includes companies at all stages of development, from early-stage companies testing transformative technologies to commercial-stage companies seeking additional growth. With a focus on areas with significant unmet need, Vertex seeks to build great companies that improve the health and quality of human life. We take an active role in our portfolio companies and work with exceptional entrepreneurs, industry partners and fellow venture investors to create value. Our global investment professionals bring deep scientific, medical and business knowledge to every investment we make. In an increasingly globalized economy, Vertex Ventures HC offers global expertise to companies around the world. With offices in Silicon Valley and Singapore, our investment team scouts and invests in promising companies in the U.S., Asia and beyond. Our team, along with our network of scientific advisors and venture partners, has deep local networks and capabilities in both emerging and established markets. Our agile structure means we can act quickly on investment opportunities.

Our goal is to help entrepreneurs turn their own ideas and visions into successful companies with fundraising and networking guidance. As a results-driven organization, we are constantly looking for ambitious and visionary partners with the drive and flexibility to take their company to the next level.

HealthCap is a European venture capital firm investing exclusively and globally in life sciences. The investment strategy focuses on diseases with high unmet medical needs and breakthrough therapies that have the potential to be transformative and change medical practice, and the lives of patients suffering these conditions. Having raised more than EUR 1.2 billion since 1996, HealthCap has backed and built more than 125 companies, taken more than 45 companies public and done numerous trade sales. Over the years, HealthCap companies have developed more than 25 pharmaceutical products to market approval, many of which are breakthrough therapies helping patients with life-threatening diseases. In addition, HealthCap companies have brought more than 50 innovative medical device products to market. These products have generated significant value to many stakeholders, including patients, physicians and society, and as a result also to HealthCap investors.